Pharming Group Reports On Preliminary Financial Results 2013

Revenues and other income decreased to €7.0 million (2012: €10.9 million) mainly as a result from lower license fees as 2012 included receipt of a €7.9 million milestone from our US partner Santarus for successful completion of study 1310 while 2013 included a €3.8 milestone from Santarus for acceptance for review of the BLA for Ruconest by the US FDA. Sales in 2013 increased to €0.9 million (2012: €0.8 million).

Help employers find you! Check out all the jobs and post your resume.